



**MANGALAM DRUGS & ORGANICS LTD.**

**Un- Audited Financial Results(Provisional) for the Quarter and Nine Month ended 31st December 2015 approved and taken on record by the Board at their meeting dated 14th January,2016**

Sr. No.	Particulars	(Rs. in Lacs)					
		Unaudited			Unaudited		Audited
		Quarter ended			NINE MONTH ENDED		Year Ended
		3 months ended	3 months ended	Corresponding 3 months ended in the previous period	figures for Current period ended	figures for the previous period ended	Previous accounting year ended
	31.12.15	30.09.15	31.12.14	31.12.15	31.12.14	31.03.15	
<b>A PART I - STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER,2015</b>							
1	Sales/Income from operation(Net of Excise duty)	8235.43	7255.60	6078.34	22447.12	14019.08	22058.39
2	Other Operating Income	0.00	0.00	216.26	2.72	488.97	7.47
3	Total Net Income from Operation	8235.43	7255.60	6294.60	22449.84	14508.05	22065.86
4	Expenditure						
	(a) Increase / decrease in stock in trade & work in progress	733.98	(1075.92)	(346.45)	409.82	552.26	(745.54)
	(b) Consumption of raw materials	5416.92	5930.01	4941.79	15723.65	9406.14	16324.04
	(c) Employee Benefits	360.72	359.17	292.31	1024.64	820.58	1095.20
	(d) Depreciation	114.98	109.45	100.27	332.68	300.80	415.40
	(e) Other expenditure	834.54	1241.70	906.45	2956.47	2292.67	3352.68
	(f) Total	7461.14	6564.41	5894.37	20447.26	13372.45	20441.78
5	Profit(+)/Loss(-) from operations before Other income,Finance cost and Exceptional Items(3-4)	774.29	691.19	400.23	2002.58	1135.60	1624.08
6	Other income	1.51	2.37	0.00	74.43	4.88	5.17
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	775.80	693.56	400.23	2077.01	1140.48	1629.25
8	Finance Cost	196.12	223.64	270.75	652.15	815.74	1028.37
9	Profit(+)/Loss(-) from ordinary activities after Finance cost but before Exceptional Items(7-8)	579.68	469.92	129.48	1424.86	324.74	600.88
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	579.68	469.92	129.48	1424.86	324.74	600.88
12	Tax Expenses(incl Deferred Tax)	200.00	105.00	45.00	375.00	60.00	(13.24)
13	Net Profit(+)/Loss(-) after Tax (11-12)	379.68	364.92	84.48	1049.86	264.74	614.12
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	379.68	364.92	84.48	1049.86	264.74	614.12
16	Paid up Equity Share Capital (face value Rs.10/-each)	1437.82	1317.82	1317.82	1437.82	1317.82	1317.82
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	0.00	0.00	0.00	1618.59
18 (i)	Earning per share (EPS) (before extraordinary items) (of ` 10/- each) (not annualised):						
	(a)Basic	2.64	2.77	0.64	7.30	2.01	4.66
	(b) Diluted	2.40	2.30	0.64	6.63	2.01	4.66
18 (ii)	Earning per share (EPS) (before extraordinary items) (of ` 10/- each) (not annualised):						
	(a)Basic	2.64	2.77	0.64	7.30	2.01	4.66
	(b) Diluted	2.40	2.30	0.64	6.63	2.01	4.66
<b>A PART II - PARTICULARS OF SHAREHOLDING</b>							
1	Non Promoters Shareholding						
	- Number of shares	7793511	7619615	7628115	7793511	7628115	7628115
	- Percentage of shareholding	54.20	57.82	57.88	54.20	57.88	57.88
2	Promoters and Promoter group Shareholding						
	a) Pledged/ Encumbered						
	Number of Shares	4050133	4050133	5491228	4050133	5491228	4050133
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	61.51	72.86	98.94	61.51	98.94	72.97
	Percentage of Shares (as a % of the total share capital of the company)	28.17	30.73	41.67	28.17	41.67	30.73
	b) Non-encumbered						
	Number of Shares	2534604	1508500	58905	2534604	58905	1500000
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	38.49	27.14	1.06	38.49	1.06	27.03
	Percentage of Shares (as a % of the total share capital of the company)	17.63	11.45	0.45	17.63	0.45	11.39
<b>B INVESTOR COMPLAINTS</b>		<b>3 Months ended 31.12.15</b>					
	Pending at the Beginning of the Quarter	Nil					
	Received during the Quarter	Nil					
	Disposed of during the Quarter	Nil					
	Remaining unresolved at the end of the Quarter	Nil					

**Notes:**

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 14th January,2016
- The above results have been subjected to limited review by Statutory Auditors.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs "the disclosure requirements of Accounting Standard(AS-17)"Segment Reporting" is not applicable.
- 12,00,000 Equity Shares are allotted on 16/11/2015 pursuant to conversion of 12,00,000 share warrants which were allotted on 28/09/2015.
- While calculating diluted EPS outstanding 14,50,000 convertible share warrants issued on Preferential basis is considered.
- The CEO & CFO have certified that the Unaudited Financial Results for the Quarter and Nine Months Ended 31st December 2015 do not contain any false or misleading statement or figures and do not omit any material facts which may make the statements or figures contained therein misleading.
- Previous year figure are regrouped wherever necessary.

On behalf of Board of Directors